Crossref
CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
Clinical Ovarian Cancer · 2011
DOI: 10.1016/j.cloc.2012.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von John Farley und 1 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Farley, J., & Birrer, M. J. (2011). CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2012.02.003
Vancouver
Farley J, Birrer MJ. CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2012.02.003
BibTeX
@article{Farley2011,
author = {Farley, John and Birrer, Michael J.},
title = {CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay},
journal = {Clinical Ovarian Cancer},
year = {2011},
doi = {10.1016/j.cloc.2012.02.003}
}
EUVIMED